mTOR inhibitors response and mTOR pathway in pancreatic neuroendocrine tumors.
about
Predictive Markers of Response to Everolimus and Sunitinib in Neuroendocrine Tumors.Everolimus as first line therapy for pancreatic neuroendocrine tumours: current knowledge and future perspectives.Anti-proliferative and anti-secretory effects of everolimus on human pancreatic neuroendocrine tumors primary cultures: is there any benefit from combination with somatostatin analogs?Gastroenteropancreatic neuroendocrine neoplasms: genes, therapies and models.
P2860
mTOR inhibitors response and mTOR pathway in pancreatic neuroendocrine tumors.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
mTOR inhibitors response and mTOR pathway in pancreatic neuroendocrine tumors.
@en
mTOR inhibitors response and mTOR pathway in pancreatic neuroendocrine tumors.
@nl
type
label
mTOR inhibitors response and mTOR pathway in pancreatic neuroendocrine tumors.
@en
mTOR inhibitors response and mTOR pathway in pancreatic neuroendocrine tumors.
@nl
prefLabel
mTOR inhibitors response and mTOR pathway in pancreatic neuroendocrine tumors.
@en
mTOR inhibitors response and mTOR pathway in pancreatic neuroendocrine tumors.
@nl
P2093
P356
P1476
mTOR inhibitors response and mTOR pathway in pancreatic neuroendocrine tumors
@en
P2093
Andrea Doria
Carmelina Di Pasquale
Corrado Rubini
Dominik Nann
Ettore Degli Uberti
Ilaria Marinoni
Maria Chiara Zatelli
Massimo Falconi
Simona Falletta
Vanessa Polenta
P304
P356
10.1530/ERC-16-0329
P577
2016-10-03T00:00:00Z